{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Any grade 3-4 toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Leukopenia and neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Fatigue"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Grade 3-4 toxicities among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)","groups":[{"description":"Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.\n\nClofarabine: Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.","id":"OG000","title":"Clofarabine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine","reportingStatus":"POSTED","timeFrame":"during 6 28-day cycles and 90 days out","title":"All Phase I-II Participants: Safety","type":"SECONDARY","unitOfMeasure":"Participants"}